Zenas Biopharma
NASDAQ: ZBIOWaltham, US · Founded 2019 · Delaware corporation · 200 employees on LinkedIn · 8 known investors
Find your way into Zenas Biopharma
32 people in our graph share verified history with the Zenas Biopharma team — schools, employers, funds. One of them is your warm intro.
Binsen Liunlockedknows HUA MU · together at Hill House (overlapped)
×2knows the team · via Hill House
×7knows the team · via University of Washington - School of Medicine
×2knows the team · via Zenas Biopharma
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor. Its products are aimed at patients with multiple autoimmune conditions with unmet medical needs.
Founders & leadership
Zenas Biopharma was founded in 2019 by LEON O. MOULDER, JR. and Lonnie Moulder.
LO
LEON O. MOULDER, JR.Co-founder
LM
Lonnie MoulderFounder, CEO & Chairman
JF
JOSEPH FARMERExecutive
HM
HUA MUinCEO, President, Acting CMO, China Head2021–2023He brings over 30 years of experience in drug development across oncology, autoimmune diseases, and neurology, with leadership roles spanning large pharmaceutical companies, biotech firms, CROs, and investment organizations in the US, Japan, and China.
Board
PG
HL
HONGBO LUBoard director
TK
TOMAS KISELAKBoard director
JJ
JP
JAMES PATRICK BOYLANBoard directorChief Executive Officer at Enavate Sciences
MW
Investors · 8
Delos CapitalCambridge
Longitude CapitalMenlo Park · $10M – $30M
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Norwest Venture PartnersMenlo Park · $10M – $30M
Quan CapitalShanghai
SR One Capital ManagementRedwood City
Vivo CapitalPalo Alto · $10M – $50M
Agent Capitalreported · 2 sourcesWalthamvia John Orloff · board
Reported raises · per SEC filings
Form D private placements$384M disclosed across 2 rounds · 2022–2024
▶$200.1MraisedMay 2024 · 26 investors · BiotechnologyRule 506(b)
▶$200.1MraisedMay 2024 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- PATRICK GERALD ENRIGHTDirector
- TOMAS KISELAKDirector
- PATRICIA ALLENDirector
- JOSEPH FARMERExecutive Officer
- LEON O. MOULDER, JR.Executive Officer, Director
- JAKE NUNNDirector
- TIM XIAODirector
- JENNIFER FOXExecutive Officer
- JAMES PATRICK BOYLANDirector
- TANYA Z. FISCHERExecutive Officer
- JOHN JACOB ORLOFFDirector
- HONGBO LUDirector
- Offering amount
- $200.1M
- Amount sold
- $200.1M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$183.9MraisedNov 2022 · 17 investors · BiotechnologyRule 506(b)
▶$183.9MraisedNov 2022 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JOSEPH FARMERExecutive Officer
- PATRICK GERALD ENRIGHTDirector
- HONGBO LUDirector
- TOMAS KISELAKDirector
- LEON O. MOULDER, JR.Director
- JOHN JACOB ORLOFFDirector
- JAMES PATRICK BOYLANDirector
- HUA MUExecutive Officer, Director
- MARIETTA WUDirector
- Offering amount
- $183.9M
- Amount sold
- $183.9M
- First sale
- Nov 2022
- Incorporated
- Other, Cayman Islands, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$676.5Mvaluation at IPOSep 2024 · $17.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 4
by search overlap
Robinhood26 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha23 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Day One Biopharmaceuticals19 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Bioworld19 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Zenas Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Zenas Biopharma do?
- Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor. Its products are aimed at patients with multiple autoimmune conditions with unmet medical needs.
- Who founded Zenas Biopharma?
- Zenas Biopharma was founded by LEON O. MOULDER, JR., Lonnie Moulder in 2019.
- Who are Zenas Biopharma's investors?
- Zenas Biopharma's investors include Delos Capital, Longitude Capital, New Enterprise Associates (NEA), Norwest Venture Partners, Quan Capital, SR One Capital Management, Vivo Capital, Agent Capital.
- How much funding has Zenas Biopharma raised?
- Zenas Biopharma has disclosed $384M raised across 2 rounds.
- Where is Zenas Biopharma headquartered?
- Zenas Biopharma is headquartered in Waltham, US.